Anti-Ebola GP [13F6-1-2]

Catalogue Number: AB02747-23.0-ABA

Manufacturer:Vector Laboratories, Inc (ABA)
Type:Recombinant Monoclonal
Alias:GP; Envelope glycoprotein
Shipping Condition:Blue Ice
Unit(s): 200 ug
Host name: Rabbit
Clone: 13F6-1-2
Isotype: IgG
Immunogen: This antibody was raised by immunizing mice with VEE virus replicon particles (VRP) that express Ebola GP (EboGP-VRP).
Application: ELISA, WB, FA, NT, SPR

Additional Text

Gene Name

GP

Purification

Purified

Gene ID

911829

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Uniprot ID

Q05320

Short Description

This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.

Application Notes

This antibody recognizes the heavily glycosylated mucin-like domain of the Ebola virus virion-attached glycoprotein (GP) and protects animals against lethal viral challenge. To determine the protective efficacy of this antibody, the mouse version of this antibody was evaluated for their ability to protect mice from a lethal Ebola challenge. The characteristics were further analyzed using radioimmunoprecipitation, western blot, and peptide-binding analysis. These assays were performed using the mouse version of this antibody and Ebola GP as antigen. Furthermore, the ability of the mouse version of this antibody to inhibit the Ebola virus from forming plaques was also determined. This indicates that this antibody can neutralize the Ebola virus (US6875433). This antibody was expressed in plants, and to show its functionality, a western blot was performed with the mouse version of this antibody (which was expressed in a plant) on Ebola virus-like particles. Further, the mouse version of this antibody was also used for ELISA on Ebola VLP. Finally, to determine the binding affinity of the mouse version of this antibody, surface plasmon resonance was performed using Ebola VLP as an antigen (Lim et al., 2020; PMID: 32977599). To assess the specific binding of this antibody, an ELISA on Ebola GP was performed using the scFv version of this antibody (Rodriguez-Martinez et al., 2015; PMID: 26489048). The structure of the mouse version of this antibody was determined using molecular replacement. Further, the binding affinity of the mouse version of this antibody was determined using surface plasmon resonance on the Ebola virus bound to BSA (Lee et al., 2008; PMID: 18005986).